In a beta thalassaemia clinical trial, integration of a SIN LV resulted in 3’ end substitution of the HMGA2 gene that abolished let7 microRNA control of this protooncogene, reduced HMGA2 degradation and subsequent clonal proliferation [18]. This evidence concerns the gene HMGA2 and beta thalassemia.